mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2021-12-2-6-15mvjr-1370Research ArticleОБЗОРЫREVIEWСердечная недостаточность с сохраненной фракцией выброса у пациентов с сахарным диабетом 2 типа: от патогенеза к лечениюHeart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment optionshttps://orcid.org/0000-0002-2397-7186БорисовА. А.BorisovA. A.

Борисов Антон Андреевич, врач-кардиолог, аспирант отдела амбулаторных лечебно-диагностических технологий, Институт клинической кардиологии им. А. Л. Мясникова

Москва

Anton A. Borisov, PhD-fellow of outpatient department of A.L. Myasnikov Institute of Clinical Cardiology

Moscow

anton.borisov.2016@gmail.comhttps://orcid.org/0000-0002-5684-9842ГвоздеваА. Д.GvozdevaA. D.

Гвоздева Анна Дмитриевна, врач-кардиолог, аспирант отдела амбулаторных лечебно-диагностических технологий, Институт клинической кардиологии им. А. Л. Мясникова

Москва

Anna D. Gvozdeva, PhD-fellow of outpatient department of A.L. Myasnikov Institute of Clinical Cardiology

Moscow

gvozdevaannalech@gmail.comhttps://orcid.org/0000-0003-4369-1393АгеевФ. Т.AgeevF. T.

Агеев Фаиль Таипович, д.м.н., профессор, главный научный сотрудник отдела амбулаторных лечебно-диагностических технологий, Институт клинической кардиологии им. А. Л. Мясникова

Москва

Fail T. Ageev, Dr. Sci. (Med.), professor of cardiology, head of outpatient department of A.L. Myasnikov Institute of Clinical Cardiology

Moscow

ftageev@gmail.comНациональный медицинский исследовательский центр кардиологииРоссияNational Medical Research Center for CardiologyRussian Federation202104072021122615Copyright © Борисов А.А., Гвоздева А.Д., Агеев Ф.Т., 20212021Борисов А.А., Гвоздева А.Д., Агеев Ф.Т.Borisov A.A., Gvozdeva A.D., Ageev F.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/1370

Сахарный диабет 2 типа не только увеличивает вероятность развития сердечной недостаточности, но и утяжеляет её течение. В то же время эффективного лечения, способного улучшать прогноз данной группы пациентов, на данный момент не существует. В обзоре представлены имеющиеся экспериментальные и клинические данные о возможном патогенезе изменений, наблюдающихся у пациентов с сердечной недостаточности с сохранённой фракцией выброса и сахарным диабетом, а также рассмотрены основные группы медицинских препаратов, в том числе экспериментальных, которые могут оказаться перспективными у данной группы больных.

Type 2 diabetes mellitus is known to increase the risk of the development of heart failure with preserved ejection fraction and worsen its symptoms. To date, no specific treatment has been shown to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction. In this review, the authors summarized the existing evidence on how diabetes mellitus can promote the development and progression of heart failure with preserved ejection fraction. The authors also addressed medications including experimental ones that can potentially be beneficial in patients of this group.

сердечная недостаточность с сохраненной фракцией выбросаСНсФВсахарный диабетиНГК-2обзорheart failure with preserved ejection fractionHFpEFdiabetes mellitusSGLT2 inhibitorsreviewРабота была выполнена при поддержке Минздрава России (протокол клинической апробации № 2018-9-25).ReferencesOwan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259. DOI: 10.1056/nejmoa052256Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259. DOI: 10.1056/nejmoa052256Zhou L, Deng W, Zhou L, Fang P, He D et al. Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review. Curr Diabetes Rev. 2009;5:171–184. DOI: 10.2174/157339909788920938Zhou L, Deng W, Zhou L, Fang P, He D et al. Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review. Curr Diabetes Rev. 2009;5:171–184. DOI: 10.2174/157339909788920938Bjorck LM, Lanitis M, Lappas G, Novak M, Rosengren A. Mortality Trends 1987 to 2004 in 404,480 Hospitalized Heart Failure Patients with and without Diabetes. Circulation. 2012;125:AP208Bjorck LM, Lanitis M, Lappas G, Novak M, Rosengren A. Mortality Trends 1987 to 2004 in 404,480 Hospitalized Heart Failure Patients with and without Diabetes. Circulation. 2012;125:AP208Dougherty AH, Naccarelli GV, Gray EL, Hicks CH, Goldstein RA. Congestive heart failure with normal systolic function. Am J Cardiol. 1984;54:778–82. DOI: 10.1016/s0002-9149(84)80207-6Dougherty AH, Naccarelli GV, Gray EL, Hicks CH, Goldstein RA. Congestive heart failure with normal systolic function. Am J Cardiol. 1984;54:778–82. DOI: 10.1016/s0002-9149(84)80207-6Soufer R, Wohlgelernter D, Vita NA, Amuchestegui M, Sostman HD, et al. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol. 1985;55(8):1032-6. doi: 10.1016/0002-9149(85)90741-6Soufer R, Wohlgelernter D, Vita NA, Amuchestegui M, Sostman HD, et al. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol. 1985;55(8):1032-6. doi: 10.1016/0002-9149(85)90741-6Borlaug BA. Heart failure with preserved ejection fraction. In: Baliga RR, Haas, GJ, eds. Management of Heart Failure. New York, NY: Springer Verlag; 2015;213–230. DOI: 10.1007/978-1-4471-6657-3_11Borlaug BA. Heart failure with preserved ejection fraction. In: Baliga RR, Haas, GJ, eds. Management of Heart Failure. New York, NY: Springer Verlag; 2015;213–230. DOI: 10.1007/978-1-4471-6657-3_11Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation: Heart Failure. 2013;6(3):606-19. DOI: 10.1161/HHF.0b013e318291329aHeidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation: Heart Failure. 2013;6(3):606-19. DOI: 10.1161/HHF.0b013e318291329aYusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81. DOI: 10.1016/S0140-6736(03)14285-7Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81. DOI: 10.1016/S0140-6736(03)14285-7Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-45. DOI: 10.1093/eurheartj/ehl250Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-45. DOI: 10.1093/eurheartj/ehl250Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67. DOI: 10.1056/NEJMoa0805450Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67. DOI: 10.1056/NEJMoa0805450Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. DOI: 10.1056/NEJMoa1313731Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. DOI: 10.1056/NEJMoa1313731Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591-602. DOI: 10.1038/nrcardio.2017.65Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591-602. DOI: 10.1038/nrcardio.2017.65Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, et al. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017;135(8):724-735. DOI: 10.1161/CIRCULATIONAHA.116.024593Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, et al. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017;135(8):724-735. DOI: 10.1161/CIRCULATIONAHA.116.024593van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117(1):43-51. DOI: 10.1161/CIRCULATIONAHA.107.728550van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117(1):43-51. DOI: 10.1161/CIRCULATIONAHA.107.728550Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016;134(1):73-90. DOI: 10.1161/CIRCULATIONAHA.116.021884Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016;134(1):73-90. DOI: 10.1161/CIRCULATIONAHA.116.021884Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World Journal of Cardiology. 2012;4:90-102. DOI: 10.4330/wjc.v4.i4.90Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World Journal of Cardiology. 2012;4:90-102. DOI: 10.4330/wjc.v4.i4.90Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670-9. DOI: 10.1093/eurheartj/ehq426Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670-9. DOI: 10.1093/eurheartj/ehq426Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932-43. DOI: 10.1161/01.ATV.0000160548.78317.29Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932-43. DOI: 10.1161/01.ATV.0000160548.78317.29Grützner A, Garcia-Manyes S, Kötter S, Badilla CL, Fernandez JM, Linke WA. Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. Biophys J. 2009;97(3):825-34. DOI: 10.1016/j.bpj.2009.05.037Grützner A, Garcia-Manyes S, Kötter S, Badilla CL, Fernandez JM, Linke WA. Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. Biophys J. 2009;97(3):825-34. DOI: 10.1016/j.bpj.2009.05.037Zhang DX, Fryer RM, Hsu AK, Zou AP, Gross GJ, et al. Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res Cardiol. 2001;96(3):267-74. DOI: 10.1007/s003950170057Zhang DX, Fryer RM, Hsu AK, Zou AP, Gross GJ, et al. Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res Cardiol. 2001;96(3):267-74. DOI: 10.1007/s003950170057Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47(6):859-66. DOI: 10.2337/diabetes.47.6.859Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47(6):859-66. DOI: 10.2337/diabetes.47.6.859Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail. 2009;2(2):129-37. DOI: 10.1161/CIRCHEARTFAILURE.108.765750Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail. 2009;2(2):129-37. DOI: 10.1161/CIRCHEARTFAILURE.108.765750Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signalling in the heart. Cardiovasc Res. 2008;79:238-248. DOI: 10.1093/cvr/cvn093Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signalling in the heart. Cardiovasc Res. 2008;79:238-248. DOI: 10.1093/cvr/cvn093Sutton MGSJ, Sharpe N. Left Ventricular Remodeling After Myocardial infarction. Circulation. 2000;101:2981. DOI: 10.1161/01.cir.101.25.2981Sutton MGSJ, Sharpe N. Left Ventricular Remodeling After Myocardial infarction. Circulation. 2000;101:2981. DOI: 10.1161/01.cir.101.25.2981Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3:853-876. DOI: 10.2147/vhrm.2008.04.01.89Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3:853-876. DOI: 10.2147/vhrm.2008.04.01.89Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, et al. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2016;4(4):312-24. DOI: 10.1016/j.jchf.2015.10.007Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, et al. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2016;4(4):312-24. DOI: 10.1016/j.jchf.2015.10.007Civitarese RA, Kapus A, McCulloch CA, Connelly KA. Role of integrins in mediating cardiac fibroblast-cardiomyocyte cross talk: a dynamic relationship in cardiac biology and pathophysiology. Basic Res Cardiol. 2017;112(1):6. DOI: 10.1007/s00395-016-0598-6Civitarese RA, Kapus A, McCulloch CA, Connelly KA. Role of integrins in mediating cardiac fibroblast-cardiomyocyte cross talk: a dynamic relationship in cardiac biology and pathophysiology. Basic Res Cardiol. 2017;112(1):6. DOI: 10.1007/s00395-016-0598-6Talior-Volodarsky I, Connelly KA, Arora PD, Gullberg D, McCulloch CA. α11 integrin stimulates myofibroblast differentiation in diabetic cardiomyopathy. Cardiovasc Res. 2012;96:265-275. DOI: 10.1093/cvr/cvs259Talior-Volodarsky I, Connelly KA, Arora PD, Gullberg D, McCulloch CA. α11 integrin stimulates myofibroblast differentiation in diabetic cardiomyopathy. Cardiovasc Res. 2012;96:265-275. DOI: 10.1093/cvr/cvs259Hölscher ME, Bode C, Bugger H. Diabetic Cardiomyopathy: Does the Type of Diabetes Matter? Int J Mol Sci. 2016;17(12):2136. DOI: 10.3390/ijms17122136Hölscher ME, Bode C, Bugger H. Diabetic Cardiomyopathy: Does the Type of Diabetes Matter? Int J Mol Sci. 2016;17(12):2136. DOI: 10.3390/ijms17122136Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. DOI: 10.1056/NEJMoa1313731Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. DOI: 10.1056/NEJMoa1313731Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly KA. Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. Can J Cardiol. 2018;34(5):632-643. DOI: 10.1016/j.cjca.2018.02.026Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly KA. Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. Can J Cardiol. 2018;34(5):632-643. DOI: 10.1016/j.cjca.2018.02.026Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. DOI: 10.1056/NEJM199909023411001Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. DOI: 10.1056/NEJM199909023411001Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/ Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res. 2016;118:1313-1326. DOI: 10.1161/circresaha.116.307708Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/ Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res. 2016;118:1313-1326. DOI: 10.1161/circresaha.116.307708Patel VB, Bodiga S, Basu R, Das SK, Wang W, et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res. 2012;110(10):1322-35. DOI: 10.1161/CIRCRESAHA.112.268029Patel VB, Bodiga S, Basu R, Das SK, Wang W, et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res. 2012;110(10):1322-35. DOI: 10.1161/CIRCRESAHA.112.268029Kalra S, Jain A, Ved J, Unnikrishnan AG. Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect. Indian J Endocrinol Metab. 2016;20:725-729. DOI: 10.4103/2230-8210.183826Kalra S, Jain A, Ved J, Unnikrishnan AG. Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect. Indian J Endocrinol Metab. 2016;20:725-729. DOI: 10.4103/2230-8210.183826Altara R, Giordano M, Nordén ES, Cataliotti A, Kurdi M, et al. Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. Front Endocrinol (Lausanne). 2017;8:160. DOI: 10.3389/fendo.2017.00160Altara R, Giordano M, Nordén ES, Cataliotti A, Kurdi M, et al. Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. Front Endocrinol (Lausanne). 2017;8:160. DOI: 10.3389/fendo.2017.00160Lim SL, Lam CS, Segers VF, Brutsaert DL, De Keulenaer GW. Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J. 2015;36:2050-2060. DOI: 10.1093/eurheartj/ehv132Lim SL, Lam CS, Segers VF, Brutsaert DL, De Keulenaer GW. Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J. 2015;36:2050-2060. DOI: 10.1093/eurheartj/ehv132Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382:1883-1893. DOI: 10.1056/NEJMoa1915928Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382:1883-1893. DOI: 10.1056/NEJMoa1915928Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, et al. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. JAMA. 2020;324(15):1512-1521. DOI: 10.1001/jama.2020.15922. Erratum in: JAMA. 2021;325(5):494.Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, et al. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. JAMA. 2020;324(15):1512-1521. DOI: 10.1001/jama.2020.15922. Erratum in: JAMA. 2021;325(5):494.Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119-1127. DOI: 10.1093/eurheartj/ehw593Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119-1127. DOI: 10.1093/eurheartj/ehw593Garcia-Egido A, Andrey JL, Puerto JL, Aranda RM, Pedrosa MJ, et al. Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. Int J Clin Pract. 2015;69(5):550-9. DOI: 10.1111/ijcp.12567Garcia-Egido A, Andrey JL, Puerto JL, Aranda RM, Pedrosa MJ, et al. Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. Int J Clin Pract. 2015;69(5):550-9. DOI: 10.1111/ijcp.12567Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J. Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis. PLoS ONE. 2014;9:e90555. DOI: 10.1371/journal.pone.0090555Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J. Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis. PLoS ONE. 2014;9:e90555. DOI: 10.1371/journal.pone.0090555Miller RJ, Howlett JG. Does heart rate really matter to patients with heart failure? Curr Opin Cardiol. 2017;32(2):209-216. DOI: 10.1097/HCO.0000000000000368Miller RJ, Howlett JG. Does heart rate really matter to patients with heart failure? Curr Opin Cardiol. 2017;32(2):209-216. DOI: 10.1097/HCO.0000000000000368Yamamoto K. Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. Yonago Acta Med. 2017;60(2):71-76. PMID: 28701888Yamamoto K. Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. Yonago Acta Med. 2017;60(2):71-76. PMID: 28701888Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59. DOI: 10.1056/NEJMoa0802743Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59. DOI: 10.1056/NEJMoa0802743Halabi A, Sen J, Huynh Q, Marwick TH. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 2020;19(1):124. DOI: 10.1186/s12933-020-01100-wHalabi A, Sen J, Huynh Q, Marwick TH. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 2020;19(1):124. DOI: 10.1186/s12933-020-01100-wEkeruo IA, Solhpour A, Taegtmeyer H. Metformin in Diabetic Patients with Heart Failure: Safe and Effective? Curr Cardiovasc Risk Rep. 2013;7(6):417-422. DOI: 10.1007/s12170-013-0355-4Ekeruo IA, Solhpour A, Taegtmeyer H. Metformin in Diabetic Patients with Heart Failure: Safe and Effective? Curr Cardiovasc Risk Rep. 2013;7(6):417-422. DOI: 10.1007/s12170-013-0355-4Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-26. DOI: 10.1056/NEJMoa1307684Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-26. DOI: 10.1056/NEJMoa1307684Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–39. DOI: 10.1016/S0140-6736(18)32590-XZelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–39. DOI: 10.1016/S0140-6736(18)32590-XFaden G, Faganello G, De Feo S, Berlinghieri N, Tarantini L, et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract. 2013;101(3):309-16. DOI: 10.1016/j.diabres.2013.07.004Faden G, Faganello G, De Feo S, Berlinghieri N, Tarantini L, et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract. 2013;101(3):309-16. DOI: 10.1016/j.diabres.2013.07.004Riggs K, Ali H, Taegtmeyer H, Gutierrez AD. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure. Metab Syndr Relat Disord. 2015;13(7):292-7. DOI: 10.1089/met.2015.0038Riggs K, Ali H, Taegtmeyer H, Gutierrez AD. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure. Metab Syndr Relat Disord. 2015;13(7):292-7. DOI: 10.1089/met.2015.0038MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377-85. DOI: 10.1093/eurheartj/ehn153MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377-85. DOI: 10.1093/eurheartj/ehn153

The authors declare that there are no conflicts of interest present.